Japanese

Short-term outcome of intravitreal injection of ranibizumab for macular edema in branch retinal vein occlusion Chihiro Ito 1 , Hiroyuki Kamao 1 , Yumi Mito 1 , Junichi Kiryu 1 1Department of Ophthalmology, Kawasaki Medical University pp.1587-1593
Published Date 2017/10/15
DOI https://doi.org/10.11477/mf.1410212443
  • Abstract
  • Look Inside
  • Reference

Abstract Purpose:To report the short-term outcome of intravitreal injection of ranibizumab for macular edema in branch retinal vein occlusion(BRVO).

Cases and Method:This retrospective study was made on 33 eyes of 33 patients who received intravitreal injection of ranibizumab for macular edema in BRVO and who were followed up for 6 months or longer. The series comprised 17 males and 16 females. The age ranged from 55 to 86 years, average 72 years. Outcome of treatment was evaluated regarding visual acuity, central retinal thickness, recurrence of macular edema, and number of sessions of ranibizumab treatment. Visual acuity was evaluated as logMAR.

Results:Visual acuity averaged 0.37±0.05 before treatment and 0.1±0.05 at the final observation. The difference was significant. Central retinal thickness averaged 529±31.75 μm before treatment and 274.5±18.0 μm at the final observation. The difference was significant. There was a positive correlation between rate of recurrence and initial visual acuity. Cases of favorable outcome showed lesser number of ranibizumab sessions. Duration between occurrence and cure was shorter in cases with better initial visual acuity.

Conclusion:Intravitreal ranibizumab injection resulted in better visual acuity and decrease in central retinal thickness following intravitreal ranibizumab injection for macular edema in BRVO.


Copyright © 2017, Igaku-Shoin Ltd. All rights reserved.

基本情報

電子版ISSN 1882-1308 印刷版ISSN 0370-5579 医学書院

関連文献

もっと見る

文献を共有